Leads Biolabs Doses First Patient in Opamtistomig Colorectal Cancer Trial
Leads Biolabs said the first patient has been dosed in an open-label Phase Ib/II combination trial of its PD-L1/4-1BB bispecific antibody in metastatic colorectal cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.